Overexpression of human epidermal growth factor receptor 2 in canine primary lung cancer

Human epidermal growth factor receptor 2 (HER2) overexpression has been reported in various human cancers. HER2-targeted therapies showed clinical responses in humans with HER2-positive tumors. The incidence of canine primary lung cancer (cPLC) is increasing, but there are no effective systemic ther...

Descripción completa

Detalles Bibliográficos
Autores principales: YOSHIMOTO, Sho, KATO, Daiki, KAMOTO, Satoshi, YAMAMOTO, Kie, TSUBOI, Masaya, SHINADA, Masahiro, IKEDA, Namiko, TANAKA, Yuiko, YOSHITAKE, Ryohei, ETO, Shotaro, SAEKI, Kohei, CHAMBERS, James, HASHIMOTO, Yuko, UCHIDA, Kazuyuki, NISHIMURA, Ryohei, NAKAGAWA, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Veterinary Science 2020
Materias:
Surgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324825/
https://www.ncbi.nlm.nih.gov/pubmed/32249253
http://dx.doi.org/10.1292/jvms.20-0026
Descripción
Sumario:Human epidermal growth factor receptor 2 (HER2) overexpression has been reported in various human cancers. HER2-targeted therapies showed clinical responses in humans with HER2-positive tumors. The incidence of canine primary lung cancer (cPLC) is increasing, but there are no effective systemic therapies for dogs with late-stage cPLC. HER2-targeted therapy could be an option for cPLC, but HER2 expression in cPLC remains unknown. We evaluated HER2 expression in cPLC. Immunohistochemical analysis revealed that 3 samples (19%) scored 3+; 8 (50%), 2+; 5 (31%); and 1+ and 0 (0%), 0. Of the cPLC tissues, 69% were HER2 positive (scored ≥2+). These data would lead to further evaluation of the role of HER2 in cPLC as a mechanism of malignancy and therapeutic target.

Ejemplares similares